



August 9, 2017

Zealand Pharma (Nasdaq: ZEAL) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, Aug. 09, 2017 (GLOBE NEWSWIRE) --

What:

Zealand Pharma (Nasdaq:ZEAL), a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, **Britt Meelby Jensen, President & CEO**, will ring the Opening Bell.

Where:

Nasdaq MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio

When:

Thursday, August 10, 2017 - 9:15 a.m. to 9:30 a.m. ET

Zealand Pharma Media Contact:

Alette Pramming

+45 53735750

apr@zealandpharma.com

Nasdaq MarketSite:

Emily Pan

(646) 441-5120

emily.pan@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:

<http://www.facebook.com/NASDAQ>.

For photos from ceremonies and events, please visit our Instagram page:

<http://instagram.com/nasdaq>

For livestream of ceremonies and events, please visit our YouTube page:

<http://www.youtube.com/nasdaq/live>

For news tweets, please visit our Twitter page:

<http://twitter.com/nasdaq>

For exciting viral content and ceremony photos, please visit our Tumblr page:

<http://nasdaq.tumblr.com/>

Webcast:

A live stream of the Nasdaq Opening Bell will be available at:

<https://new.livestream.com/nasdaq/live> or <http://www.nasdaq.com/about/marketsitetowervideo.aspx>

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to <http://business.nasdaq.com/discover/market-bell-ceremonies> and click on the market open of your choice.

About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen:ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua® 100/33 in the U.S. and has been approved as Suliqua® in Europe and launched in the Netherlands.

Zealand's clinical pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 3); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); and dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system to reduce the risk of hypoglycemia and better diabetes management (Phase 2) and other indications, as well as other earlier-stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately \$12 trillion. To learn more, visit:

<http://business.nasdaq.com>

-NDAQ-

 Primary Logo

Source: NASDAQ, Inc.

News Provided by Acquire Media